VitaNova Life Sciences Corp, originally operating at losses with limited scale, achieved a striking turnaround with a 487.6% increase in operating income by FY2025 despite a sharp 68.3% revenue decline. The company’s business spans consulting advisory services and anti-aging healthcare products focused on NAD+ level enhancement, marketed via a diverse multi-channel strategy including e-commerce, physical retail, and direct sales. While operational leverage and margin expansion have driven recent profitability gains, growth is tempered by scale constraints, absence of insurance coverage, and reliance on brand development rather than R&D. Monitoring international expansion progress and sustaining cash flows will be crucial for VitaNova's future trajectory.